Responding to questions from The Cancer Letter, Jim Newman, director of external communications at MD Anderson, confirmed that the presentation obtained by The Cancer Letter was prepared under a contract by McKinsey & Company.
A group of melanoma experts, joined by three advocacy groups focused on melanoma, has engaged FDA in a public discussion of the challenges of developing new drugs in the refractory setting and the role crossover can play in such trials.
